UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2023

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)

Israel	**001-16174**	**Not Applicable**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification Number)**

124 Dvora Hanevi'a Street
Tel Aviv 6944020, Israel
(Address of Principal Executive Offices, including Zip Code)

+972- 3-914-8213
(Registrant's Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Copies of communications to:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
American Depositary Shares, each representing one Ordinary Share	TEVA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Departure of Dr. Sven Dethlefs, Executive Vice President, North America Commercial

Dr. Sven Dethlefs, Executive Vice President, North America Commercial, will be leaving Teva. Dr. Dethlefs plans to remain in his role until November 17, 2023. Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial.

ITEM 7.01 Regulation FD Disclosure

Appointment of Ms. Christine Fox, Executive Vice President, U.S. Commercial

On September 28, 2023, Teva issued a press release announcing that Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the "Commission") and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description of Document
99.1	Press release of the Company issued on September 28, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Date: September 28, 2023

By:	/s/ Eli Kalif
Name:	Eli Kalif
Title:	Executive Vice President, Chief Financial Officer

Exhibit 99.1

TEVA ANNOUNCES CHANGES TO EXECUTIVE MANAGEMENT TEAM

TEL AVIV, Israel & PARSIPPANY, N.J., September 28, 2023 — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a heralded pharmaceutical executive with extensive experience growing and overseeing complex business units and regional operations throughout the world. I have every confidence that Chris will bring great strength to Teva and be pivotal to our success."

Biography: Christine Fox

Christine (Chris) Fox comes to Teva as Executive Vice President, U.S. Commercial Business from her role at Novartis Gene Therapies where she started as President in December 2021. Prior to this role, Chris was vice president and general manager for the Bone, Cardiometabolic and Nephrology business for Amgen. She also served as the general manager of the company's United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda, and several startups.

Chris brings more than 30 years of healthcare industry experience with leadership roles in sales, marketing, and commercial operations, responsible for teams ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance, or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our business and operations in general, including our ability to attract, hire, integrate

IR Contacts	**United States**	Ran Meir	(267) 468-4475
		Sanjeev Sharma	(93) 524-1908
PR Contacts	**United States**	Kelley Dougherty	(973) 658-0237
		Yonatan Beker	(973) 264 7378

and retain highly skilled personnel; our ability to successfully compete in the marketplace; our substantial indebtedness; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our quarterly report on Form 10-Q for the second quarter of 2023, and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

# # #

IR Contacts	**United States**	Ran Meir	(267) 468-4475
		Sanjeev Sharma	(93) 524-1908
PR Contacts	**United States**	Kelley Dougherty	(973) 658-0237
		Yonatan Beker	(973) 264 7378